Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: Secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid

Clinical Therapeutics

Volumn 36, Issue 9, 2014, Pages

  Niederman, Michael S ^a   Chastre, Jean ^b   Solem, Caitlyn T ^c   Wan, Yin ^c   Gao, Xin ^c   Myers, Daniela E ^d   Haider, Seema ^d   Li, Jim Z ^d   Stephens, Jennifer M ^c  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b Institut de Cardiologie   (France)

^c PHARMERIT INTERNATIONAL   (United States)

^d PFIZER INC   (United States)

Author keywords

Cost effectiveness; Economics; MRSA; Nosocomial pneumonia; Outcomes; Renal failure

Indexed keywords

LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NOSOCOMIAL PNEUMONIA; PHASE 4 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; CROSS INFECTION; ECONOMICS; HEALTH CARE PLANNING; MICROBIOLOGY; PNEUMONIA, STAPHYLOCOCCAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; HEALTH RESOURCES; HUMANS; LINEZOLID; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RENAL DIALYSIS; RENAL INSUFFICIENCY; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84908608544     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.029     Document Type: Article

References (25)

1. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81-S87.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-292.
3. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-1279.
4. Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin Ther. 2012;34:149-157.
5. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrobial Agents Chemother. 2011;55:5475-5479.
6. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9:9-14.
7. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-426.
8. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
9. Shen WC, Chiang YC, Chen HY, et al. Nephrotoxicity of vancomycin in patients with methicillin]resistant Staphylococcus aureus bacteraemia. Nephrology. 2011;16:697-703.
10. Zyvox (package insert). New York, NY: Pfizer; 2012.
11. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621-629.
12. First Databank Inc. [database online]. South San Francisco, CA: First Databank, Inc; 2012.
13. Ingenix. Ingenix National Fee Analyzer. Eden Prairie, MN: Ingenix (part of Optuminsight); 2012.
14. Candrilli S, Mauskopf J. How much does a hospital day cost? Value Health. 2006:A56.
15. Yu W, Ravelo A, Wagner TH, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev. 2003;60:146S-167S.
16. Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo M. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease nontraditional host. J Med Econ. 2011; 14:227-237.
17. Ahmed Z, Gilibert S, Krevolin L. Cost analysis of continuous renal replacement and extended hemodialysis. Dial Transplant. 2009;38: 500-503.
18. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
19. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993.
20. Ramsey S, Willke R, Briggs A, et al. Good research practices for costeffectiveness analysis alongside clinical trials: the ISPOR RCTCEA Task Force report. Value Health. 2005;8:521-533.
21. Niederman MS, Wunderink RG, Chastre JE, et al. Outcomes of vancomycin weight-based dosing by trough concentrations for the treatment of hospital-acquired pneumonia caused by methicillinresistant Staphylococcus aureus. Paper presented at: American Thoracic Society International Conference; 2011; Denver, Colorado.
22. Mullins CD, Kuznik A, Shaya FT, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillinresistant Staphylococcus aureus. Clin Ther. 2006;28:1184-1198.
23. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med. 2004;32:137-143.
24. Stock GN, McDermott C. Operational and contextual drivers of hospital costs. J Health Organ Manag. 2011;25:142-158.
25. Wilke MH, Grube R. Pharmacoeconomic evaluation of antibiotic therapy strategies in DRG-based healthcare systems - a new approach. Eur J Med Res. 2010;15: 564-570.